KD 025

Drug Profile

KD 025

Alternative Names: KD-025; SLX-2119

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Surface Logix
  • Developer Kadmon Pharmaceuticals
  • Class Antifibrotics; Antineoplastics; Antipsoriatics; Antirheumatics; Small molecules
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Graft-versus-host disease; Idiopathic pulmonary fibrosis; Plaque psoriasis
  • Phase I Scleroderma; Systemic lupus erythematosus
  • Discontinued Autoimmune disorders; Non-alcoholic steatohepatitis; Rheumatoid arthritis

Most Recent Events

  • 06 Oct 2017 KD 025 receives Orphan Drug status for Graft-versus-host disease in USA
  • 25 Jul 2017 Supplemental interim efficacy data from a phase II trial in Graft versus host disease released by Kadmon Pharmaceuticals
  • 11 Jul 2017 Interim safety efficacy data from a phase II trial in Graft versus host disease released by Kadmon
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top